Table 5

Mean proportion of days controlled

Mean percentage of days controlled during weeks 5–12 (95% CI) Measure of control
Study[Ref.]TreatmentLevel 1Level 2
A1 9 a SFC34 (26–42)51 (42–60)
SALM10 (5–15)19 (13–26)
FP13 (8–19)30 (22–38)
PL8 (3–13)13 (7–19)
A2 10 b SFC36 (28–45)56 (47–65)
SALM10 (5–15)16 (10–22)
FP20 (13–27)33 (24–42)
PL7 (4–10)16 (10–22)
B1 11 SFC37 (31–44)46 (39–53)
SALM + FP concurrently41 (34–48)50 (43–57)
B2 12 SFC26 (21–31)36 (30–42)
SALM + FP concurrently22 (18–27)31 (26–36)
B3 13 SFC21 (16–26)31 (25–37)
SALM + FP concurrently22 (17–27)30 (24–36)
FP17 (12–22)23 (18–28)
B4 14 SFC44 (38–50)55 (49–61)
SALM + FP concurrently43 (37–49)54 (48–60)
C1 15 SFC44 (38–50)51 (45–57)
BUD40 (34–46)50 (44–56)
C2 16 SFC31 (26–36)41 (35–47)
BUD20 (15–25)27 (22–33)
  • 95% CI: confidence interval; a: approximately 70% of patients were previously taking inhaled corticosteroids; b: all patients were previously taking inhaled corticosteroids; BUD: budesonide; FP: fluticasone propionate; PL: placebo; SALM: salmeterol; SFC: salmeterol/fluticasone propionate combination product.